Avidicure starts with $50 million for novel cancer antibody work

24 April 2025

Dutch biotech Avidicure has launched with $50 million in seed financing to support development of a novel class of multifunctional antibody therapies for cancer.

The funding round, announced Thursday, was led by EQT Life Sciences and joined by Kurma Partners, BioGeneration Ventures, and others. The firm’s most advanced program, AVC-S-101, is currently in preclinical development for non-small-cell lung cancer and other solid tumors.

The company said it will present early data at upcoming oncology conferences, including the American Association for Cancer Research meeting and the American Society of Clinical Oncology annual event.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK